Bacterial membrane vesicles for vaccine applications

Krishnan, Nishta; Kubiatowicz, Luke J.; Holay, Maya; Zhou, Jiarong; Fang, Ronnie H.; Zhang, Liangfang

doi:10.1016/j.addr.2022.114294

Cited by 43 publications

(30 citation statements)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MCNPs are similar in composition to the mouse BMDCs from which the membranes were derived. MCNPs have been widely reported using cell sources from bacterial cells, cancer cells, blood cells, and T cells (Johnson et al, 2021; Krishnan et al, 2022; Zhang et al, 2020; Zhou et al, 2022); however, fewer studies have focused on using APCs such as DCs, and DCregs in particular, as the cell source for T cell communication (Li et al, 2021). The fabricated MCNPs are spherical structure with a diameter of approximately 400 nm, which are larger than many other MCNPs (Xiao et al, 2021) yet substantially smaller than the typical BMDCs with dimension ranging from 15 to 20 µm (Szakal et al, 1985).…”

Section: Discussionmentioning

confidence: 99%

Membrane‐coated nanoparticles for direct recognition by T cells

Urie

et al. 2022

Biotech & Bioengineering

View full text Add to dashboard Cite

The direct modulation of T cell responses is an emerging therapeutic strategy with the potential to modulate undesired immune responses including, autoimmune disease, and allogeneic cells transplantation. We have previously demonstrated that poly(lactide‐co‐glycolide) particles were able to modulate T cell responses indirectly through antigen‐presenting cells (APCs). In this report, we investigated the design of nanoparticles that can directly interact and modulate T cells by coating the membranes from APCs onto nanoparticles to form membrane‐coated nanoparticles (MCNPs). Proteins within the membranes of the APCs, such as Major Histocompatibility Complex class II and co‐stimulatory factors, were effectively transferred to the MCNP. Using alloreactive T cell models, MCNP derived from allogeneic dendritic cells were able to stimulate proliferation, which was not observed with membranes from syngeneic dendritic cells and influenced cytokine secretion. Furthermore, we investigated the engineering of the membranes either on the dendritic cells or postfabrication of MCNP. Engineered membranes could be to promote antigen‐specific responses, to differentially activate T cells, or to directly induce apoptosis. Collectively, MCNPs represent a tunable platform that can directly interact with and modulate T cell responses.

show abstract

Section: Discussionmentioning

confidence: 99%

Membrane‐coated nanoparticles for direct recognition by T cells

Urie

et al. 2022

Biotech & Bioengineering

View full text Add to dashboard Cite

show abstract

“…EVs activate inflammatory responses by activating TLRs ( 100 ) ( Figure 3 ). TLRs sense microbial components, such as nucleic acids, LPSs, peptidoglycans and EVs.…”

Section: Bacteria Evs In the Prevention Of Tumorsmentioning

confidence: 99%

“…These TLRs can be decorated on EVs or carried as transmitters by them. As a result of these microbial factors, tolerance may be promoted or signalling pathways leading to chronic inflammation may be activated ( 100 ).…”

Section: Bacteria Evs In the Prevention Of Tumorsmentioning

confidence: 99%

“…During laser ablation, a large amount of cancer antigens is released for immune priming after their accumulation in tumours ( 121 ). Through thrombosis and erythrocyte extravasation, Salmonella typhimurium -derived EVs sensitise tumours to photothermal therapy even in the absence of photothermal agents ( 59 , 100 , 122 ). To enhance the effectiveness of EVs, radiation therapy can also be used, which is considered a purely external method for destroying tumours.…”

Section: Bacterial Evs and Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Bacteria derived extracellular vesicles in the pathogenesis and treatment of gastrointestinal tumours

Sun

Zhao

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Extracellular vesicles are fundamentally significant in the communication between cells. Outer Membrane Vesicles(OMVs) are a special kind of EVs produced by Gram-negative bacteria, which are minute exosome-like particles budding from the outer membrane, which have been found to play essential roles in diverse bacterial life events, including regulation of microbial interactions, pathogenesis promotion, stress responses and biofilm formation. Recently, and more researches have explored the substantial potentials of EVs as natural functional nanoparticles in the bioengineering applications in infectious diseases, cardiovascular diseases, autoimmune diseases and neurological diseases, such as antibacterial therapy, cancer drugs and immunoadjuvants, with several candidates in clinical trials showing promising efficacy. However, due to the poor understanding of sources, membrane structures and biogenesis mechanisms of EVs, progress in clinical applications still remains timid. In this review, we summarize the latest findings of EVs, especially in gastrointestinal tract tumours, to provide a comprehensive introduction of EVs in tumorigenesis and therapeutics.

show abstract

“…can be found in the tumor microenvironment. Recent studies have also demonstrated the role of bacteria in the tumor microbe microenvironment [ 158 , 159 ]. Therefore, selecting the right cell source (RBCs, immune cells, cancer cells, bacteria, etc.)…”

Section: Introductionmentioning

confidence: 99%

Biomimetic cell-derived nanocarriers in cancer research

et al. 2022

View full text Add to dashboard Cite

Nanoparticles have now long demonstrated capabilities that make them attractive to use in biology and medicine. Some of them, such as lipid nanoparticles (SARS-CoV-2 vaccines) or metallic nanoparticles (contrast agents) are already approved for their use in the clinic. However, considering the constantly growing body of different formulations and the huge research around nanomaterials the number of candidates reaching clinical trials or being commercialized is minimal. The reasons behind being related to the “synthetic” and “foreign” character of their surface. Typically, nanomaterials aiming to develop a function or deliver a cargo locally, fail by showing strong off-target accumulation and generation of adverse responses, which is connected to their strong recognition by immune phagocytes primarily. Therefore, rendering in negligible numbers of nanoparticles developing their intended function. While a wide range of coatings has been applied to avoid certain interactions with the surrounding milieu, the issues remained. Taking advantage of the natural cell membranes, in an approach that resembles a cell transfer, the use of cell-derived surfaces has risen as an alternative to artificial coatings or encapsulation methods. Biomimetic technologies are based on the use of isolated natural components to provide autologous properties to the nanoparticle or cargo being encapsulated, thus, improving their therapeutic behavior. The main goal is to replicate the (bio)-physical properties and functionalities of the source cell and tissue, not only providing a stealthy character to the core but also taking advantage of homotypic properties, that could prove relevant for targeted strategies. Such biomimetic formulations have the potential to overcome the main issues of approaches to provide specific features and identities synthetically. In this review, we provide insight into the challenges of nano-biointerfaces for drug delivery; and the main applications of biomimetic materials derived from specific cell types, focusing on the unique strengths of the fabrication of novel nanotherapeutics in cancer therapy. Graphical Abstract

show abstract

Bacterial membrane vesicles for vaccine applications

Cited by 43 publications

References 174 publications

Membrane‐coated nanoparticles for direct recognition by T cells

Membrane‐coated nanoparticles for direct recognition by T cells

Bacteria derived extracellular vesicles in the pathogenesis and treatment of gastrointestinal tumours

Biomimetic cell-derived nanocarriers in cancer research

Contact Info

Product

Resources

About